Study: ‘Dropless’ therapy could save billions of dollars for Medicare, Medicaid and patients

Using a one-time injection to replace antibiotic and anti-inflammation eye drop therapy associated with cataract surgery has the potential for saving government payers and patients billions of dollars over time, according to an economic impact study cited by Imprimis Pharmaceuticals in a press release.The study, promulgated by Cataract Surgeons for Improved Eyecare and funded in part by Imprimis Pharmaceuticals, found that over 10 years, potential cost savings for patients, Medicare and Medicaid was “a most likely savings estimate of $8.7 billion.”